KROS Rinvatercept Phase 3 Data, Rinvatercept MDS+AML, Rinvatercept Obesity+Fibrosis, Rinvatercept ALS+DMD
Keros Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $10.90
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS